Why the study?
What are the pharmacokinetic properties of oral and intravenous amiodarone in healthy volunteers and patients with supraventricular tachycardia?
Population
9 individuals (3 healthy volunteers and 6 patients with supraventricular tachycardia)
Design
Other
Follow-up
Up to 50 hours
Authors
Loading...
Supports monitoring amid variable bioavailability; extends PK data in SVT patients but leaves optimal regimens open.
What are the pharmacokinetic properties of oral and intravenous amiodarone in healthy volunteers and patients with supraventricular tachycardia?
Amiodarone has a large volume of distribution, a long elimination half-life, and highly variable oral bioavailability, which informs its clinical dosing strategy.
Riva et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: